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CD44 is a family of cell-surface adhesion molecules which
exist in several isoforms arising from mRNA alternative.
Malignant transformation of colonic mucosa is associated
with alterations in CD44 expression, which result in up-reg-
ulation of high-molecular-weight CD44 isoforms and down-
regulation of CD44s. We have demonstrated that stable
transfection of CD44s into colon-carcinoma cell lines reduces
their tumorigenicity. To understand the influence of CD44s
expression on the metastatic potential of human colon car-
cinomas, we measured the ability of several different CD44s-
transfected colon carcinomas to establish experimental liver
metastases following splenic inoculation in mice. We ob-
served that introduction of CD44s into 2 different human
colon carcinoma cell lines, HT29 and KM12C6, resulted in
reduced growth of liver metastases by as much as 75%. To
explore the relationship between hyaluronate adhesion and
metastasis, we transfected HT29 cells with cDNA encoding a
mutant CD44s that does not bind to hyaluronate. HT29
transfectants expressing this mutant CD44s demonstrate an
84% reduction in growth of liver metastases, despite minimal
binding to hyaluronate by the mutant CD44s. In concert,
these results indicate that CD44s down-regulation, which
occurs with malignant transformation of colonic mucosa, is
associated with enhanced growth of experimental liver me-
tastases. Consequently, the functional consequences of
CD44s down-regulation in colon carcinomas may be just as
significant as the consequences of up-regulation of other
CD44 isoforms. Int. J. Cancer 85:523–526, 2000.
© 2000 Wiley-Liss, Inc.
CD44 is a family of cell-surface adhesion molecules encoded by
a single gene. Several CD44 isoforms exist as a result of alterna-
tive splicing, thereby providing significant heterogeneity in CD44
expression among different tissues. The breadth of CD44 post-
translational modifications that exist adds to the diversity of CD44
molecules that may be expressed on cell surfaces (Brown et al.,
1991). The most common CD44 isoform is present on cells of
hematopoetic origin and does not contain any of the alternatively
spliced exons that encode a portion of the extracellular domain.
The transcript for this standard isoform, referred to as CD44s (and
also known as CD44H), contains exon 5 spliced directly to exon
16. In contrast, inclusion of different combinations of variant
exons between exon 5 and exon 16 results in seemingly countless
higher-molecular-weight CD44 isoforms. CD44 is broadly distrib-
uted in normal and malignant tissues; however, malignant trans-
formation is frequently associated with alterations in CD44 alter-
native splicing (Dall et al., 1994; Tanabe et al., 1993). Several
investigators have examined the correlation between CD44-iso-
form-expression patterns and tumor stage in patients with lym-
phoma, gastric carcinoma, breast cancer, and colon carcinoma
(Friedrichs et al., 1995; Jalkanen et al., 1991; Miwa et al., 1996;
Wielenga et al., 1993). The mechanisms that lead to these associ-
ations have yet to be determined.
CD44s is expressed in normal colon mucosa, but this expression
is either lost or down-regulated as a result of malignant transfor-
mation (Tanabe et al., 1995). To study the phenotypic conse-
quences of CD44s down-regulation in colon carcinoma, we trans-
fected colon-carcinoma cell lines with CD44s cDNA to
reintroduce expression of this adhesion molecule. Introduction of
CD44s cDNA into colon-cancer cell lines restores cell-surface
expression of CD44s and reduces their tumorigenicity (Takahashi
et al., 1995; Tanabe et al., 1995). The ability of CD44s expression
to reduce tumorigenicity may correlate with its ability to bind to
hyaluronate (Takahashi et al., 1995). These observations prompted
us to test whether the introduction of CD44s into colon carcinomas
might also reduce growth of experimental liver metastases. We
now demonstrate that cell-surface expression of the CD44s adhe-
sion molecule reduces tumor growth in the liver after splenic
inoculation of human colon-carcinoma cells. By using a mutant
form of CD44s that is incapable of adhesion to hyaluronate, we
determined that this reduction in formation and growth of liver
metastases is independent of its ability to bind to hyaluronate. Our
earlier findings indicate that transformation of normal colonic
mucosa to carcinoma is associated with alterations in CD44 alter-
native splicing that result in down-regulation of CD44s. Together,
our findings suggest that modulation of CD44 alternative splicing
is one mechanism that may enhance tumor metastases.
MATERIAL AND METHODS
Cell lines, transfectants, and antibodies
The human colon-carcinoma cell line HT29 was obtained from
the ATCC (Rockville, MD). The human colon-carcinoma clones
KM12C6 and KM12L4 are related (Morikawa et al., 1988a) and
were kindly provided by Dr I. Fidler (MD Anderson Cancer
Center, Houston, TX). All cell lines were maintained in DMEM/
F12 with glutamine (GIBCO BRL, Gaithersburg, MD) supple-
mented with 8% (v/v) FCS (GIBCO BRL) with an appropriate
concentration of G418 (Sigma, St. Louis, MO). HT29Dneo,
HT29DCD44s, KM12C6Dneo, KM12C6DCD44s, KM12L4Dneo
and KM12L4DCD44s transfectants have been described (Taka-
hashi et al., 1995). The MAbs F10-44-2 (Biodesign International,
Kennebunk, ME) and BU52 (Binding Site, San Diego, CA) are
directed against epitopes common to all CD44 isoforms. The
construct containing cDNA for mutant CD44s with arginine 41
mutated to alanine has been described (Takahashi et al., 1996) and
was introduced into HT29 cells by electroporation. Cell-surface
CD44 expression was examined on all G418-resistant clones.
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Confirmation of cell-surface expression of CD44
Immunoprecipitation of cell-surface labeled proteins to confirm
expression of CD44 on stable transfectants was performed as
described (Takahashi et al., 1995).
FACS analysis
Cells were harvested with 5 mM EDTA in PBS, and single-cell
suspensions were incubated with MAb BU52 on ice for 30 min.
After washing, cells were incubated with fluorescein-labeled anti-
mouse MAb (Sigma) on ice for 30 min. Immunofluorescence was
detected with FACScan (Becton Dickinson, Mountain View, CA).
Adhesion assay
Cell-surface CD44 binding to hyaluronate was examined in
96-well flat-bottomed plates coated with hyaluronate, as described
(Takahashi et al., 1999).
Experimental-liver-metastasis assay
5 week old male BALB/c nude mice (Steele Laboratory, Mas-
sachusetts General Hospital, Boston, MA) were allowed to accli-
matize for one week. Transfectants were harvested using only 5
mM EDTA in PBS without trypsin and re-suspended as a single-
cell suspension in Hanks’s balanced salt solution, free of Mg21
and Ca21. After induction of general anesthesia with methoxyflu-
rane, a left subcostal incision was performed on the mice, the
spleen was exposed, and cells were inoculated intrasplenically.
The mice were observed for the indicated time period, at which
point their livers were harvested through a midline incision. Ex-
periments were performed in duplicate.
Statistical analyses
The number of liver lobes containing metastases were compared
using Fisher’s exact test (InStat; Graphpad Software, New York, NY).
RESULTS
CD44s expression reduces metastatic tumor growth in the liver
To examine the influence of CD44s expression on metastasis,
we established an experimental-liver-metastasis assay for each of
3 human colon-carcinoma cell lines. We have established stable
transfectants that express CD44s (designated with the suffix
DCD44s) using HT29, KM12C6 and KM12L4 human colon-
carcinoma cell lines (Takahashi et al., 1995). We confirmed cell-
surface expression of CD44s by immunoprecipitation of cell-
surface labeled proteins using CD44 MAb F10-44-2 (data not
shown). Pilot experiments were performed to establish the optimal
technique for establishing experimental liver metastases with these
cell lines. We performed a number experiments, varying several
conditions, including the number of cells implanted into the
spleen; trypsin vs. no trypsin to harvest cells; splenectomy vs. no
splenectomy following tumor-cell inoculation; and number of
weeks until animals were killed. Liver metastases were typically
too numerous to count, and their distribution among lobes and
throughout any given lobe were too heterogeneous to permit
evaluation of the percentage volume replacement of the liver by
tumor. When we decreased the number of cells implanted into the
spleen, the standard deviation for the number of liver metastases
became unacceptably high. The liver surface area occupied by
tumor was taken as a reproducible endpoint. For HT29 transfec-
tants, 5 3 106 cells were inoculated intrasplenically and mice were
killed 20 days later. All mice inoculated with HT29 transfectants
developed liver metastases; however, the extent of metastases
differed significantly (Table I). Mice inoculated with HT29Dneo
cells developed more liver metastases, with 24 of 40 lobes (60%)
demonstrating tumor replacement of at least one quarter of the
lobe. In mice inoculated with HT29DCD44s cells, only 6 of 40
lobes (15%) demonstrated tumor replacement of at least one quar-
ter of the lobe (p , 0.0001). The metastatic deposits in the liver
were too numerous to count. Also, the metastatic foci were not
evenly distributed throughout each lobe, but rather were concen-
trated near the periphery of each lobe in the subcapsular region.
In a similar experimental-liver-metastasis assay, 1 3 106
KM12C6 or KM12L4 transfectants were inoculated intraspleni-
cally, and mice were killed 30 days later. Out of 8 mice inoculated
with KM12C6Dneo cells, 5 developed liver metastases, as com-
pared with only 2 of 8 mice inoculated with KM12C6DCD44s
cells. When KM12L4 transfectants were compared, 2 of 8 mice
inoculated with KM12L4Dneo cells and 2 of 7 mice inoculated
with KM12L4DCD44s cells developed liver metastases of similar
magnitude. Because of the lower experimental metastatic potential
of KM12L4 cells in our assay, compared with the KM12C6 and
HT29 transfectants, we were not able to determine with statistical
significance whether CD44s expression on KM12L4 cells reduces
their metastatic potential as it does when expressed on KM12C6 or
HT29 cells. Presumably, differences in our experimental-metasta-
sis assay compared with that used originally to develop the
KM12L4 cells (Morikawa et al., 1988b) accounts for our finding
of a lower metastatic potential of KM12L4 cells compared to
KM12C6 cells. For example, we did not use trypsin to harvest the
cells, since it cleaves cell-surface CD44 (data not shown). None-
theless, the reduction in HT29 and KM12C6 metastatic tumor
growth in the liver as a result of cell-surface CD44s expression
was quite apparent.
Relationship between CD44s hyaluronate adhesion and growth
of liver metastases
The relationship between CD44s adhesion to hyaluronate and
growth of liver metastases is interesting, especially when the above
results are viewed with the knowledge that CD44s expressed on
HT29 cells and KM12C6 cells effectively binds to hyaluronate,
while CD44s expressed on KM12L4 cells does not effectively bind
hyaluronate (Takahashi et al., 1995). To better explore the rela-
tionship between hyaluronate binding and growth of liver metas-
tases we used a mutant form of CD44s with a single amino-acid
substitution in the B loop (hyaluronate-binding) domain that re-
duces its adhesion to hyaluronate. This mutation involves a change
from arginine at residue 41 to alanine (Peach et al., 1993). We
transfected HT29 cells with cDNA encoding this mutant CD44s
and isolated G418-resistant clones (designated with the suffix
D41R/A). We confirmed the presence of cell-surface mutant
CD44s by immunoprecipitation (Fig. 1a) and confirmed that this
mutant CD44s does not bind to hyaluronate as well as wild-type
CD44s (Fig. 1b). HT29D41R/A transfectants (5 3 106) were in-
oculated intrasplenically into nude mice, which were killed 20
days later. All mice inoculated with HT29D41R/A transfectants
developed liver metastases (as did all mice inoculated with either
HT29Dneo or HT29DCD44s transfectants). However, in mice
inoculated with HT29D41R/A transfectants, only 3 of 32 lobes
(9.4%) showed tumor replacement of at least one quarter of the
lobe, which is essentially identical to the results obtained using
HT29DCD44s (Table I). All our results combined suggest that
CD44s expression on human colon-carcinoma cells reduces the
growth of experimental liver metastases, and that this reduction is
not dependent on the hyaluronate-binding function of CD44.
DISCUSSION
Multiple steps are required for successful hematogenous metas-
tasis, including detachment from the primary tumor, degradation
TABLE I – EXPERIMENTAL LIVER METASTASES
Transfectant
Mice with
liver metastases
(%)
Hepatic lobes
with .25 covered
with metastases
(%)
HT29Dneo 10/10 (100.0) 24/40 (60.0)
HT29DCD44s 10/10 (100.0) 6/40 (15.0)
HT29D41R/A 8/8 (100.0) 3/32 (9.4)
KM12C6Dneo 5/8 (62.5) 0/32 (0.0)
KM12C6DCD44s 2/8 (25.0) 0/32 (0.0)
KM12L4Dneo 2/8 (25.0) 0/32 (0.0)
KM12L4DCD44s 2/7 (28.6) 0/28 (0.0)
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of extracellular matrix, migration, invasion into blood vessels,
survival from host defense mechanisms, adhesion to the endothe-
lium in distant organs, and growth in the new organ environment.
The process of metastasis is modulated by communication be-
tween tumor-cell-adhesion molecules and the extracellular envi-
ronment. CD44 appears to be involved in several steps of the
metastatic cascade. Experimental data from in vitro models of
invasion and metastases suggest that CD44 expression influences
tumor-cell migration (Thomas et al., 1992), MMP-2 production
(Takahashi et al., 1999), invasion (Yu and Stamenkovic, 1999),
presentation of heparin-binding growth factors (Bennett et al.,
1995a), adhesion to peritoneal mesothelium (Cannistra et al.,
1993), and hyaluronate degradation (Culty et al., 1992).
A number of investigators have examined the role of CD44 in
metastases, using in vivo assays. Most notably, Günthert et al.
(1991) demonstrated that over-expression of a v6-containing
CD44 isoform by rat pancreatic-carcinoma cells enhances their
metastatic potential. Of note, the rat pancreatic-carcinoma clone
with low metastatic potential that was used in this study expressed
CD44s. In contrast, using a different animal model, Sy et al.
(1991) demonstrated that Namalwa lymphoma cells transfected to
over-express CD44s show greater metastatic potential than paren-
tal cells. Birch et al. (1991) demonstrated that melanoma cells
selected for high expression of CD44s demonstrate a greater
metastatic potential than cells selected for low expression of
CD44s. At first glance, results of these published experiments
appear to be at odds with the results presented in the current study.
We observed that expression of CD44s by different human colon-
carcinoma cell lines reduces their metastatic potential. However, it
should be recognized that significant differences exist between the
models used in each of these studies, including differences in the
tumor cell lines and host animals. Many traits are required of
metastatic cells, and individual tumor cell lines presumably differ
in the array of necessary metastatic traits that they lack. Conse-
quently, a specific CD44 isoform may be necessary to complement
the inherent metastatic traits of one cell line, and a different CD44
isoform may be necessary to complement those of another cell
line. In addition, specific CD44 post-translational modifications
(e.g., glycosylation and glycosaminoglycan substitution) directly
modulate CD44 function (Bennett et al., 1995b; Dasgupta et al.,
1996; Takahashi et al., 1996). Significant heterogeneity exists in
the spectrum of post-translational machinery existing in different
types of tumors. Consequently, it follows that any correlation
between CD44 expression and metastatic potential will depend on
CD44 post-translational modification in the particular tumor cell line.
The association between CD44s expression and down-regula-
tion of metastases has been reported by Gao et al. (1997) using a
different experimental-metastasis model. These investigators dem-
onstrated that experimental down-regulation of CD44s in Dunning
rat prostate-cancer cells enhances their metastatic potential, and
that up-regulation of CD44s in the highly metastatic Dunning
AT3.1 clone greatly suppresses its metastatic potential. This ob-
served down-regulation of prostate-cancer metastases with CD44s
expression is very similar in concept to our findings that CD44s
expression reduces growth of experimental liver metastases. In
addition, Souka et al. (1997) demonstrated that down-regulation or
complete loss of CD44 expression is associated with enhanced cell
proliferation, while Jalkanen et al. (1991) reported that rapidly
proliferating, highly aggressive non-Hodgkin’s lymphomas often
do not express CD44.
CD44 is the main cell-surface receptor for hyaluronate and
contains sequences homologous with the B domain of cartilage
link protein, which is responsible for hyaluronate binding (Peach et
al., 1993). Now, experimental results demonstrate that enhanced
hyaluronate binding is not required for the suppression of meta-
static potential induced by over-expression of CD44s in Dunning
AT3.1 cells (Gao et al., 1998). The absence of a consistent asso-
ciation between CD44s adhesion to hyaluronate and down-regu-
lation of metastases reported by these authors is in line with our
own findings in human colon-carcinoma cells.
Several high-molecular-weight CD44 isoforms have been iden-
tified in human tumors, and many investigators have been inter-
ested in the phenotypic consequences of over-expression of these
variant CD44 isoforms. In contrast, we observed that in addition to
variant CD44-isoform over-expression, transformation of colonic
mucosa to carcinoma is associated with down-regulation of
CD44s. We have focused many of our investigations on the con-
sequences of this CD44s down-regulation. We demonstrated ear-
lier that reintroduction of CD44s into colon-carcinoma cell lines is
associated with a 50% reduction in their tumorigenicity and
growth rate (Takahashi et al., 1995). Consequently, the reduction
in bulk of HT29DCD44s liver metastases observed in the present
FIGURE 1 – CD44s expression on HT29 cells and hyaluronate
adhesion. (a) Cell lysates from HT29Dneo, HT29DCD44s, or
CD44D41R/A cells were subjected to immunoprecipitation, the MAb
F10-44-2 being used after labeling of cell-surface proteins with biotin.
(b) HT29 transfectants were examined for their adhesion to solid-
phase hyaluronate.
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study could in theory be partially attributable simply to a reduction
in tumor-cell growth rate. However, the finding that HT29D41R/A
transfectants demonstrate in vitro growth rates similar to those of
HT29Dneo transfectants, yet demonstrate a reduction in liver me-
tastases, argues against this possibility, as does the reduction in the
number of mice developing metastases following injection with
KM12C6DCD44s transfectants, as compared with controls.
The finding that CD44s expression results in down-regulation of
metastatic tumor growth in the liver in 2 unrelated human colon-
carcinoma cell lines makes it unlikely that our results may be
explained solely on the basis of clonal variation. Moreover, intro-
duction of mutant CD44s into HT29 cells produced similar obser-
vations. Nonetheless, at this point it is premature to speculate on
the mechanisms by which reintroduction of CD44 into colon
carcinomas reduces their tumorigenicity and metastatic potential.
The mechanism does not appear to be related to CD44 adhesion to
hyaluronate.
In summary, alterations in CD44 alternative splicing associ-
ated with transformation of colonic mucosa to carcinoma result
in up-regulation of variant CD44 isoforms that have been im-
plicated in tumor metastases. In addition, malignant transfor-
mation is associated with down-regulation of CD44s. Introduc-
tion of CD44s into colon-carcinoma cells reduces their
tumorigenicity and the growth of experimental liver metastases.
Accordingly, the functional consequences of CD44s down-
regulation in colon carcinomas may be just as significant as the
consequences of up-regulation of other CD44 isoforms in tumor
progression.
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